FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

Radiopharmaceutical developer Telix Pharmaceuticals Ltd (ASX:TLX) is expanding its push into AI-enabled cancer imaging ...

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging ...

Telix Pharmaceuticals (ASX:TLX) announced a collaboration with University Hospital Essen to develop AI based prognostic models using PSMA PET imaging in prostate cancer. The company has also submitted ...

The post Stagflation Fears Emerge-Market Analysis for March 9th, 2026 appeared first on Stock Target Advisor.

This stock is making its shareholders smile on Tuesday. Let's find out why. The post Why is this ASX 200 share charging 7% higher today? appeared first on The Motley Fool Australia.

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...